Target-specific oral anticoagulants in atrial fibrillation: Results of phase III trials and comments on sub-analyses Journal Article


Author: Mantha, S.
Article Title: Target-specific oral anticoagulants in atrial fibrillation: Results of phase III trials and comments on sub-analyses
Abstract: Dabigatran, rivaroxaban, apixaban and edoxaban administered in fixed doses and without routine laboratory monitoring have been compared to warfarin for the prevention of stoke in patients with nonvalvular atrial fibrillation (AF). Phase III data is currently available for dabigatran, rivaroxaban and apixaban. It is derived from three randomized controlled trials: RE-LY, ROCKET AF and ARISTOTLE. Dabigatran and apixaban appeared to be superior to warfarin for the primary endpoint of stroke or systemic embolism, while rivaroxaban was deemed non-inferior. The risk of major bleeding was modestly decreased overall with the new agents, while the risk of intracranial hemorrhage was substantially reduced. The results of ENGAGE AF-TIMI 48 comparing edoxaban to warfarin are still pending. Large, well designed clinical trials support the use of three new target-specific oral anticoagulants for the prevention of stroke in individuals with nonvalvular AF. © 2013 Springer Science+Business Media New York.
Keywords: stroke; anticoagulation; atrial fibrillation
Journal Title: Journal of Thrombosis and Thrombolysis
Volume: 36
Issue: 2
ISSN: 0929-5305
Publisher: Springer  
Date Published: 2013-08-01
Start Page: 155
End Page: 162
Language: English
DOI: 10.1007/s11239-013-0925-9
PROVIDER: scopus
PUBMED: 23595515
DOI/URL:
Notes: --- - "Export Date: 4 September 2013" - "CODEN: JTTHF" - "Source: Scopus"
Altmetric
Citation Impact
MSK Authors
  1. Simon H Mantha
    46 Mantha